



Mithra Announces the Appointment of its Representative to Mayne Pharma's Board of Directors

Liege, Belgium, 4 October 2021 – 17:45 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women's Health, is pleased to announce that it has joined the Board of Mayne Pharma Group Limited, in accordance with the license and supply agreement to commercialize Nextstellis® (E4/DRSP) oral contraceptive in the United States¹. As Mayne Pharma's largest shareholder (9.6% stake), Mithra has appointed Dr. Carolyn Myers as Director on the Board, as well as on the joint steering committee related to the commercialization and continued development of Nextstellis®.

Dr. Myers, a U.S. resident, has been supporting Mithra's business development and marketing strategy for several years. She is an experienced pharmaceutical executive having held senior leadership roles at Allergan, Forest Labs, Mylan (now Viatris) and Pharmacia (now Pfizer). With over 30 years of experience in the pharmaceutical industry, she is currently CEO of FendX technologies, a medical technology company formed to develop and commercialize products using a unique pathogen-repelling technology. She is also Principal of BioEnsemble, providing consulting services to small and mid-size pharma, biotech and medical technology companies. Previously, she held the positions of Vice President of Global Alliance Management and International Business Development at Allergan, Vice President of Marketing at Forest Laboratories, President of Dey Laboratories and President of Mylan Technologies. She holds a Ph.D. from the University of British Columbia and a Master's in Business Administration from Rutgers University.

Commenting on her appointment, Dr. Myers said: *"I am pleased to be joining the Board at this important time in Mayne Pharma's development. As nominee of the Company's largest shareholder, our interests are aligned. I am committed to supporting the successful commercialization of Nextstellis® oral contraceptive in the world's largest pharmaceutical market."*

Mayne Pharma's Chair Mr. Frank Condella said: *"We are delighted to welcome Carolyn to the Board of Mayne Pharma. Carolyn has a distinguished track record of success in creating, growing, and leading healthcare businesses. She has a deep experience in business development, sales and marketing, strategy, portfolio management and R&D and has led the launch of over 20 brand products."*

For more information, please contact:

Benoît Mathieu (IRO) : +32 473 35 80 18 - investorrelations@mithra.com

Maud Vanderthommen (Press) : +32 473 58 61 04 – press@mithra.com

¹ [Mithra press release. 01/10/2019](#)

About Mithra

Mithra (Euronext: MITRA) is a Belgian biotech company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Mithra explores the potential of the unique native estrogen Estetrol in a wide range of applications in women health and beyond (Covid-19, neuroprotection...). Mithra also develops and manufactures complex therapeutics in the areas of contraception, menopause and hormone-dependent cancers. It offers partners a complete spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO. Active in more than 100 countries around the world, Mithra has an approximate headcount of 300 staff members and is headquartered in Liège, Belgium. www.mithra.com

Important information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.



News
Alerts

Subscribe to our mailing list on investors.mithra.com to receive our press releases by email or follow us on our social media :

[Linkedin](#) • [Twitter](#) • [Facebook](#)